Table 3.
Treatment response of bevacizumab plus irinotecan for patients with GBM
| Study | Median OS (range), weeks/months | Predicted mOS | Survival gain | Weighted gain |
|---|---|---|---|---|
| Bokstein et al47 | 7 m (95% CI 1.7–16) | 7, 37 | −0, 37 | −1, 67 |
| Desjardins et al42 | 65 w | 13, 74 | 2, 46 | 14, 13 |
| Friedman et al43 | 8.7 m (95% CI 7.8–10.9) | 7, 88 | 0, 82 | 7, 38 |
| Kreisl et al44 | 31 w (95% CI 21–54) | 7, 11 | 0, 59 | 4, 09 |
| Poulsen et al48 | 30 w (95% CI 24–37) | 10, 75 | −3, 25 | −23, 41 |
| Vredenburg et al45 | 42 w (95% CI 35–60) | 4, 44 | 1, 56 | 9, 24 |
| Vredenburg et al38 | 40 w | 7, 66 | −1, 96 | −11, 09 |
Abbreviations: GBM, glioblastoma multiforme; OS, overall survival; w, weeks; m, months; CI, confidence interval; mOS, median OS.